By SPC Staff
The FDA granted a new indication for daratumumab (Darzalex, Janssen/Genmab A/S) in combination with lenalidomide (Revlimid, Celgene) and dexamethasone (Rd) for the treatment of patients with newly diagnosed multiple myeloma (MM) who are ineligible for autologous stem cell transplant (ASCT).